Targeting Angiogenesis in Childhood Sarcomas

Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors...

Full description

Bibliographic Details
Main Authors: Hemant K. Bid, Peter J. Houghton
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Sarcoma
Online Access:http://dx.doi.org/10.1155/2011/601514
id doaj-4ce4523cedd74f2c94f7d7e444e8c109
record_format Article
spelling doaj-4ce4523cedd74f2c94f7d7e444e8c1092020-11-24T22:29:53ZengHindawi LimitedSarcoma1357-714X1369-16432011-01-01201110.1155/2011/601514601514Targeting Angiogenesis in Childhood SarcomasHemant K. Bid0Peter J. Houghton1Center for Childhood Cancer, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USACenter for Childhood Cancer, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USAAngiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.http://dx.doi.org/10.1155/2011/601514
collection DOAJ
language English
format Article
sources DOAJ
author Hemant K. Bid
Peter J. Houghton
spellingShingle Hemant K. Bid
Peter J. Houghton
Targeting Angiogenesis in Childhood Sarcomas
Sarcoma
author_facet Hemant K. Bid
Peter J. Houghton
author_sort Hemant K. Bid
title Targeting Angiogenesis in Childhood Sarcomas
title_short Targeting Angiogenesis in Childhood Sarcomas
title_full Targeting Angiogenesis in Childhood Sarcomas
title_fullStr Targeting Angiogenesis in Childhood Sarcomas
title_full_unstemmed Targeting Angiogenesis in Childhood Sarcomas
title_sort targeting angiogenesis in childhood sarcomas
publisher Hindawi Limited
series Sarcoma
issn 1357-714X
1369-1643
publishDate 2011-01-01
description Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.
url http://dx.doi.org/10.1155/2011/601514
work_keys_str_mv AT hemantkbid targetingangiogenesisinchildhoodsarcomas
AT peterjhoughton targetingangiogenesisinchildhoodsarcomas
_version_ 1725742859878924288